Located at the Alexion Campus in College Park, the €306 million plant will "transform the development and commercialisation of new medicines," the British-Swedish company known for their COVID-19 vaccine said in a statement.
100 high skill jobs in the fields of science and engineering are expected to be created at the facility.
The news was welcomed by Taoiseach Micheál Martin.
"In choosing Ireland as the location for its new next-generation active pharmaceutical ingredient manufacturing facility, AstraZeneca joins the very strong and successful network of global life sciences companies we have in Ireland," he said. "I wish them every success with their operations here."
AstraZeneca CEO Pascal Soriot said the new facility will "nurture the country’s dynamic life sciences sector and allow for the development of high value-added medicines."
Astrazeneca say the new plant will be designed in a way that facilitates the manufacture of a wide range of medicines. It will reduce costs and lead times and allow for more sustainable manufacturing processes.
"The future manufacturing of APIs for our medicines includes compounds with highly complex synthesis, requiring next generation technologies and capabilities that can respond quickly and nimbly to rapidly-changing clinical and commercial needs," said the company's executive vice president Pam Cheng.
